Importance: Although plenty of data exist regarding clinical manifestations, course, case fatality rate, and risk factors associated with mortality in severe coronavirus disease 2019 (COVID-19), long-term respiratory and functional sequelae in survivors of COVID-19 are unknown. Objective: To evaluate the prevalence of lung function anomalies, exercise function impairment, and psychological sequelae among patients hospitalized for COVID-19, 4 months after discharge. Design, Setting, and Participants: This prospective cohort study at an academic hospital in Northern Italy was conducted among a consecutive series of patients aged 18 years and older (or their caregivers) who had received a confirmed diagnosis of severe acute respiratory coronavirus 2 (SARS-CoV-2) infection severe enough to require hospital admission from March 1 to June 29, 2020. SARS-CoV-2 infection was confirmed via reverse transcription-polymerase chain reaction testing, bronchial swab, serological testing, or suggestive computed tomography results. Exposure: Severe COVID-19 requiring hospitalization. Main Outcomes and Measures: The primary outcome of the study was to describe the proportion of patients with a diffusing lung capacity for carbon monoxide (Dlco) less than 80% of expected value. Secondary outcomes included proportion of patients with severe lung function impairment (defined as Dlco <60% expected value); proportion of patients with posttraumatic stress symptoms (measured using the Impact of Event Scale-Revised total score); proportion of patients with functional impairment (assessed using the Short Physical Performance Battery [SPPB] score and 2-minute walking test); and identification of factors associated with Dlco reduction and psychological or functional sequelae. Results: Among 767 patients hospitalized for severe COVID-19, 494 (64.4%) refused to participate, and 35 (4.6%) died during follow-up. A total of 238 patients (31.0%) (median [interquartile range] age, 61 [50-71] years; 142 [59.7%] men; median [interquartile range] comorbidities, 2 [1-3]) consented to participate to the study. Of these, 219 patients were able to complete both pulmonary function tests and Dlco measurement. Dlco was reduced to less than 80% of the estimated value in 113 patients (51.6%) and less than 60% in 34 patients (15.5%). The SPPB score was suggested limited mobility (score <11) in 53 patients (22.3%). Patients with SPPB scores within reference range underwent a 2-minute walk test, which was outside reference ranges of expected performance for age and sex in 75 patients (40.5%); thus, a total of 128 patients (53.8%) had functional impairment. Posttraumatic stress symptoms were reported in a total of 41 patients (17.2%). Conclusions and Relevance: These findings suggest that at 4 months after discharge, respiratory, physical, and psychological sequelae were common among patients who had been hospitalized for COVID-19.
Importance: Although plenty of data exist regarding clinical manifestations, course, case fatality rate, and risk factors associated with mortality in severe coronavirus disease 2019 (COVID-19), long-term respiratory and functional sequelae in survivors of COVID-19 are unknown. Objective: To evaluate the prevalence of lung function anomalies, exercise function impairment, and psychological sequelae among patients hospitalized for COVID-19, 4 months after discharge. Design, Setting, and Participants: This prospective cohort study at an academic hospital in Northern Italy was conducted among a consecutive series of patients aged 18 years and older (or their caregivers) who had received a confirmed diagnosis of severe acute respiratory coronavirus 2 (SARS-CoV-2) infection severe enough to require hospital admission from March 1 to June 29, 2020. SARS-CoV-2 infection was confirmed via reverse transcription-polymerase chain reaction testing, bronchial swab, serological testing, or suggestive computed tomography results. Exposure: Severe COVID-19 requiring hospitalization. Main Outcomes and Measures: The primary outcome of the study was to describe the proportion of patients with a diffusing lung capacity for carbon monoxide (Dlco) less than 80% of expected value. Secondary outcomes included proportion of patients with severe lung function impairment (defined as Dlco <60% expected value); proportion of patients with posttraumatic stress symptoms (measured using the Impact of Event Scale-Revised total score); proportion of patients with functional impairment (assessed using the Short Physical Performance Battery [SPPB] score and 2-minute walking test); and identification of factors associated with Dlco reduction and psychological or functional sequelae. Results: Among 767 patients hospitalized for severe COVID-19, 494 (64.4%) refused to participate, and 35 (4.6%) died during follow-up. A total of 238 patients (31.0%) (median [interquartile range] age, 61 [50-71] years; 142 [59.7%] men; median [interquartile range] comorbidities, 2 [1-3]) consented to participate to the study. Of these, 219 patients were able to complete both pulmonary function tests and Dlco measurement. Dlco was reduced to less than 80% of the estimated value in 113 patients (51.6%) and less than 60% in 34 patients (15.5%). The SPPB score was suggested limited mobility (score <11) in 53 patients (22.3%). Patients with SPPB scores within reference range underwent a 2-minute walk test, which was outside reference ranges of expected performance for age and sex in 75 patients (40.5%); thus, a total of 128 patients (53.8%) had functional impairment. Posttraumatic stress symptoms were reported in a total of 41 patients (17.2%). Conclusions and Relevance: These findings suggest that at 4 months after discharge, respiratory, physical, and psychological sequelae were common among patients who had been hospitalized for COVID-19.
Authors: S Nica; A Albu; C Ştefani; I A Eremia; F A Cofaru; M I Nica; C M Ciornei; D G Cimponeriu; R I Nica Journal: Acta Endocrinol (Buchar) Date: 2022 Apr-Jun Impact factor: 1.104
Authors: Marta Núñez-Fernández; Cristina Ramos-Hernández; Francisco García-Río; María Torres-Durán; Andrés Nodar-Germiñas; Amara Tilve-Gómez; Paula Rodríguez-Fernández; Diana Valverde-Pérez; Alberto Ruano-Raviña; Alberto Fernández-Villar Journal: J Clin Med Date: 2021-05-14 Impact factor: 4.241
Authors: Amaya Jimeno-Almazán; Jesús G Pallarés; Ángel Buendía-Romero; Alejandro Martínez-Cava; Francisco Franco-López; Bernardino J Sánchez-Alcaraz Martínez; Enrique Bernal-Morel; Javier Courel-Ibáñez Journal: Int J Environ Res Public Health Date: 2021-05-17 Impact factor: 3.390
Authors: Tiziano Barbui; Alessandra Iurlo; Arianna Masciulli; Alessandra Carobbio; Arianna Ghirardi; Giuseppe Rossi; Claire Harrison; Alberto Alvarez-Larran; Elena Maria Elli; Jean-Jaques Kiladjian; Mercedes Gasior Kabat; Alberto Marin Sanchez; Francesca Palandri; Marcio Miguel Andrade-Campos; Alessandro Maria Vannucchi; Gonzalo Carreno-Tarragona; Petros Papadopoulos; Keina Quiroz Cervantes; Maria Angeles Foncillas; Maria Laura Fox; Miguel Sagues Serrano; Elisa Rumi; Santiago Osorio; Giulia Benevolo; Andrea Patriarca; Begona Navas Elorza; Valentin Garcia-Gutierrez; Elena Magro Mazo; Francesca Lunghi; Massimiliano Bonifacio; Valerio De Stefano; Juan Carlos Hernandez-Boluda; Emma Lopez Abadia; Anna Angona; Blanca Xicoy Cirici; Marco Ruggeri; Steffen Koschmieder; Marta Anna Sobas; Beatriz Cuevas; Daniele Cattaneo; Rosa Daffini; Marta Bellini; Natalia Curto-Garcia; Marta Garrote; Fabrizio Cavalca; Lina Benajiba; Beatriz Bellosillo; Paola Guglielmelli; Oscar Borsani; Silvia Betti; Silvia Salmoiraghi; Alessandro Rambaldi Journal: Blood Cancer J Date: 2021-06-16 Impact factor: 11.037